

PUBBLICAZIONI 2009

1. Fanales-Belasio E., Moretti S., Fiorelli V., Tripiciano A, Pavone-Cossut M.R., Scoglio A., Collacchi B., Nappi F., Macchia I., Bellino S., Francavilla V., Caputo A., Barillari G., Magnani M., Laguardia M.E., Cafaro A., Titti F., Monini P., Ensoli F., and Ensoli B. HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response which appears prevalent in the asymptomatic stage of infection. J. Immunol., 182:2888-2897, 2009.
2. Monini P., Sgadari C., Grosso M.G., Bellino S., Di Biagio A., Toschi E., Bacigalupo I., Sabbatucci M., Cencioni G., Salvi E., Leone P., and Ensoli B. for the Concerted Action on Kaposi's Sarcoma (Barillari G., Moracci G., Carratelli L., Gatti G., Brambilla L., Brambati M., Ferrucci S., De Pità O., Pilla M.A., Di Carlo A., Giuliani M., Cottoni F., Cuccuru M.A., Calvieri S., Clerico R., Potenza C., Tirelli U., Simonelli C., Martellotta F., Borghi A., Del Giacco S., Moi L., Piludu G., Sirianni M.C., Campagna M., Sarmati L., Andreoni M., Bianchini G., Sheldon J., Milzer J., Schulz T.). Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor Indinavir. AIDS J., 23:534-538, 2009.
3. Florese R.H., Demberg T., Xiao P., Kuller L., Larsen K., Summers E.L., Venzon D., Cafaro A., **Ensoli B.**, and Robert-Guroff M. Contribution of non-neutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared to multigenic vaccines. J. Immunol., 182:3718-27, 2009.
4. Borsetti A., Baroncelli S., Maggiorella M.T., Moretti S., Fanales Belasio E., Sernicola L., Tripiciano A., Macchia I., Michelini Z., Belli R., Farcomeni S., Pavone-Cossut M.R., Negri D., Caputo A., Bellino S., Butto' S., Titti F., Cafaro A., and **Ensoli B.** Containment of infection in Tat vaccinated monkeys after rechallenge with a higher dose of SHIV89.6P_{cy243}. Viral Immunol., 22:117-24, 2009
5. Longo O., Tripiciano A., Fiorelli V., Bellino S., Scoglio A., Collacchi B., Ruiz Alvarez M.J., Francavilla V., Arancio A., Paniccia G., Lazzarin A., Tambussi G., Tassan Din C., Visintini R., Narciso P., Antinori A., D'Offizi G., Giulianelli M., Carta M., Di Carlo A., Palamara G., Giuliani M., Laguardia M.E., Monini P., Magnani M., Ensoli F., and **Ensoli B.** Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. Vaccine (special issue, from the: "6th World Congress on Vaccines, Immunisation and Immunotherapy 2008", Milan, Italy; September 23-September 25, 2008), 27:3306-3312, 2009.
6. Titti F., Hammer D.S. HIV/AIDS vaccine: rumors and insights on a T-cell-based vaccine. Future Virol. 4(2): 121-126, 2009
7. Caputo A., Castaldello A., Brocca-Cofano E., Voltan R., Bortolazzi F., Altavilla G., Sparnacci K., Laus M., Tondelli L., Gavioli R., Ensoli B. Induction of humoral and enhanced cellular immune responses by novel core-shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration. Vaccine, 27: 3605-3615, 2009

8. Voltan R., Castaldello A., Brocca-Cofano E., De Michele R., Triulzi C., Altavilla G., Tondelli L., Laus M., Sparnacci K., Reali E., Gavioli R., Ensoli B., and Caputo A. Priming with a very low dose of DNA complexed with cationic block copolymers followed by protein boost elicits broad and long-lasting antigen-specific humoral and cellular responses in mice. Vaccine, 27: 4498-4507, 2009
9. Cafaro A., Macchia I., Maggiorella M.T., Titti F., and **Ensoli B.** Innovative approaches to develop prophylactic and therapeutic vaccines against HIV/AIDS. *In: Pharmaceutical Biotechnology* (Guzman C.A. and Fuerstein G. Eds.), Chapter No. 14, pp. 189-242, Publisher: Landes Bioscience/Eurekah, USA, 2009.
10. De Maria A., Ugolotti E., Rutjens E., Mazza S., Radic L., Faravelli A., Koopman G., Di Marco E., Costa P., Ensoli B., Cafaro A., Mingari M.C., Moretta L., Heeney J., Biassoni R. NKp44 expression, phylogenesis and function in non-human primate NK cells. Int. Immunology, 21:245-255, 2009.
11. Ridolfi B., Catone S., Sgarbanti M., Sernicola L., Battistini A., Parolin C., Titti F., Borsetti A. Generation of a human immunodeficiency virus type 1 chronically infected monkey B cell line expressing low levels of endogenous TRIM5 α . J. Cell Physiol. 221:760-765, 2009
12. Caputo A., Gavioli R., Bellino S., Longo O., Tripiciano A., Francavilla V., Sgadari C., Paniccia G., Titti F. Cafaro A., Ferrantelli F., Monini P., Ensoli F., and **Ensoli B.** HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development. Int. Reviews Immunol., 28:285–334, 2009.
13. Nappi F., Chiozzini C., Bordignon V., Borsetti A., Bellino S., Cippitelli M., Barillari G., Caputo A., Tyagi M., Giacca M., and **Ensoli B.** Immobilized HIV-1 Tat protein promotes gene transfer via a transactivation-independent mechanism which require binding of Tat to viral particles. J. Gene Med., 11: 955–965, 2009.
14. Barillari G., Toschi E., Sgadari C., Monini P. and **Ensoli B.** The formation of new blood vessels in Kaposi's sarcoma. *In: The Research Signpost* (Kaposi Sarcoma: A model of Oncogenesis, 2010; Stebbing J., Pantanowitz L., Dezube B. Eds.), Publisher: The Research Signpost, USA, Chapter 6, pp. 101-122, 2009.
15. **Ensoli B.**, Fiorelli V., Ensoli F., Lazzarin A., Visintini R., Narciso P., Di Carlo A., Tripiciano A., Longo O., Bellino S., Francavilla V., Paniccia G., Arancio A., Scoglio A., Collacchi B., Ruiz Alvarez M.J., Tambussi G., Tassan Din C., Palamara G., Latini A., Antinori A., D'Offizi G., Giuliani M., Giulianelli M., Carta M., Monini P., Magnani M., and Garaci E. The preventive phase I trial with the HIV-1 Tat based vaccine. Vaccine, 28:371–378, 2009.
16. Bellino S., Francavilla V., Tripiciano A., Paniccia G., Arancio A., Fiorelli V., Scoglio A., Collacchi B., Campagna M., Lazzarin A., Tambussi G., Tassan Din C., Visintini R., Narciso P., Antinori A., D'Offizi G., Giulianelli M., Carta M., Di Carlo A., Palamara G., Giuliani M., Laguardia M.E., Monini P., Magnani M., Ensoli F., and **Ensoli B.** Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate. Recent Rev. Clin. Trials, 4:195-204, 2009.